DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Treatment-Resistant Hypertension (TRH) Market Insights, Epidemiology, and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of Treatment-Resistant Hypertension (TRH), including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Treatment-Resistant Hypertension (TRH) Market
The market size for Treatment-Resistant Hypertension (TRH) in the leading markets is expected to grow significantly by 2036.
The United States accounted for the highest Treatment-Resistant Hypertension (TRH) treatment market size in the 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
DelveInsight’s analysis estimates that the Treatment-Resistant Hypertension (TRH) market size in the 7MM was approximately USD 7 billion in 2025 and is expected to increase substantially during the forecast period owing to the uptake of newly approved and emerging therapies.
Based on DelveInsight’s assessment in 2025, the 7MM had approximately 13 million diagnosed prevalent cases of Treatment-Resistant Hypertension (TRH).
In the 7MM, the United States accounted for nearly 56% of the total diagnosed prevalent Treatment-Resistant Hypertension (TRH) cases in 2025, followed by EU4 and the UK (24%) and Japan (20%).
According to NHS England (2021), 30% of adults had hypertension, including 15% with untreated hypertension, with a similar prevalence observed among men and women.
In Japan, there were approximately 1.2 million diagnosed prevalent male cases and 1.4 million diagnosed prevalent female cases of Treatment-Resistant Hypertension (TRH) in 2025.
In the United States, patients aged 60 years and above represented the largest diagnosed patient population, followed by those aged 40–59 years, while individuals aged 18–39 years accounted for the smallest share.
Leading Treatment-Resistant Hypertension (TRH) companies, such as AstraZeneca, Mineralys Therapeutics, E-Star BioTech, Ionis Pharmaceuticals, Kardigan, Alnylam Pharmaceuticals, Roche, and Idorsia Pharmaceuticals, are developing innovative therapies expected to transform the Treatment-Resistant Hypertension (TRH) market over the coming years.
The promising Treatment-Resistant Hypertension (TRH) therapies in clinical development include Baxdrostat (CIN-107), Lorundrostat (MLS-101), MANP, Tonlamarsen (ION904), Zilebesiran, and others.
Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/treatment-resistant-hypertension-market
Key Factors Driving the Treatment-Resistant Hypertension (TRH) Market
Increasing Prevalence of Hypertension and Cardiometabolic Disorders: The rising incidence of hypertension, obesity, diabetes, chronic kidney disease, and aging populations has significantly increased the burden of Treatment-Resistant Hypertension (TRH). These factors contribute to persistent uncontrolled blood pressure despite the use of multiple antihypertensive agents.
Growing Demand for Novel Mechanism-based Therapies: Conventional antihypertensive therapies often fail to adequately control blood pressure in resistant patients. The approval of TRYVIO (aprocitentan) and the development of aldosterone synthase inhibitors, RNA-based therapeutics, and natriuretic peptide analogs are expanding treatment options for patients with resistant disease.
Advancements in Precision Cardiovascular Therapeutics: The Treatment-Resistant Hypertension (TRH) pipeline is rapidly evolving with innovative therapies targeting the endothelin pathway, aldosterone synthase, angiotensinogen, and natriuretic peptide signaling. These therapies are expected to improve blood pressure control while reducing cardiovascular and renal complications.
Treatment-Resistant Hypertension (TRH) Competitive Landscape
Several Treatment-Resistant Hypertension (TRH) therapies are currently under clinical development, including Baxdrostat (AstraZeneca), Lorundrostat (Mineralys Therapeutics), MANP (E-Star BioTech), Tonlamarsen (Ionis Pharmaceuticals and Kardigan), and Zilebesiran (Alnylam Pharmaceuticals and Roche).
These investigational therapies target multiple pathways involved in resistant hypertension, including aldosterone synthase inhibition, endothelin receptor antagonism, angiotensinogen silencing, and natriuretic peptide receptor activation. Their differentiated mechanisms of action have the potential to provide greater blood pressure reduction and improved cardiovascular outcomes compared with currently available therapies.
Discover more about therapies set to grab major Treatment-Resistant Hypertension (TRH) market share @ Treatment-Resistant Hypertension (TRH) Treatment Landscape
Recent Developments in the Treatment-Resistant Hypertension (TRH) Market
In December 2025, AstraZeneca announced that the US FDA accepted the New Drug Application (NDA) for Baxdrostat under Priority Review, with a PDUFA decision expected during the second quarter of 2026.
In July 2025, AstraZeneca announced that Baxdrostat met the primary and all secondary endpoints in the Phase III BaxHTN trial involving patients with uncontrolled or Treatment-Resistant Hypertension.
In December 2025, Mineralys Therapeutics announced that its Phase III Launch-HTN trial of Lorundrostat was recognized among JAMA’s Research of the Year, following significant reductions in blood pressure and a favorable safety profile.
In February 2025, E-Star BioTech announced that the first patient had been dosed in the Phase II BOLD-HTN trial evaluating MANP for Treatment-Resistant Hypertension.
In March 2025, the US FDA removed the REMS requirement for TRYVIO (aprocitentan), reflecting increased regulatory confidence in the therapy’s benefit-risk profile.
What is Treatment-Resistant Hypertension (TRH)?
Treatment-Resistant Hypertension (TRH) is a clinical condition in which blood pressure remains above target levels despite treatment with at least three antihypertensive medications of different classes, including a diuretic, administered at maximally tolerated doses. Some patients also require four or more medications to achieve adequate blood pressure control. TRH is associated with an increased risk of cardiovascular disease, stroke, heart failure, chronic kidney disease, and premature mortality. Current management combines lifestyle modifications, optimization of antihypertensive therapy, mineralocorticoid receptor antagonists, and recently approved endothelin receptor antagonists such as TRYVIO, while several novel therapies are being developed to improve long-term disease control.
Treatment-Resistant Hypertension (TRH) Epidemiology Segmentation
The Treatment-Resistant Hypertension (TRH) epidemiology section provides insights into the historical and current Treatment-Resistant Hypertension (TRH) patient pool and forecasted trends for the leading markets. The Treatment-Resistant Hypertension (TRH) market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Total Diagnosed Prevalent Cases of Treatment-Resistant Hypertension (TRH)
Gender-specific Diagnosed Prevalent Cases of Treatment-Resistant Hypertension (TRH)
Age-specific Diagnosed Prevalent Cases of Treatment-Resistant Hypertension (TRH)
Severity-specific Diagnosed Prevalent Cases of Treatment-Resistant Hypertension (TRH)
Scope of the Treatment-Resistant Hypertension (TRH) Market Report
Therapeutic Assessment: Treatment-Resistant Hypertension (TRH) current marketed and emerging therapies
Treatment-Resistant Hypertension (TRH) Market Dynamics: Key Market Forecast Assumptions of Emerging Treatment-Resistant Hypertension (TRH) Drugs and Market Outlook
Key Companies: AstraZeneca, Mineralys Therapeutics, E-Star BioTech, Ionis Pharmaceuticals, Kardigan, Alnylam Pharmaceuticals, Roche, Idorsia Pharmaceuticals, Janssen Pharmaceuticals, George Medicines, and others
Key Therapies: Baxdrostat (CIN-107), Lorundrostat (MLS-101), TRYVIO (Aprocitentan), MANP, Tonlamarsen (ION904), Zilebesiran, GMRX2, and others
Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies
Unmet Needs, KOL’s Views, Analyst’s Views, Treatment-Resistant Hypertension (TRH) Market Access and Reimbursement
To know more about Treatment-Resistant Hypertension (TRH) companies working in the treatment market, visit @ Treatment-Resistant Hypertension (TRH) Clinical Trials and Therapeutic Assessment
Table of Contents
Treatment-Resistant Hypertension (TRH) Market Report Introduction
Executive Summary for Treatment-Resistant Hypertension (TRH)
SWOT Analysis of Treatment-Resistant Hypertension (TRH)
Treatment-Resistant Hypertension (TRH) Patient Share (%) Overview at a Glance
Treatment-Resistant Hypertension (TRH) Market Overview at a Glance
Treatment-Resistant Hypertension (TRH) Background and Overview
Treatment-Resistant Hypertension (TRH) Epidemiology and Patient Population
Country-Specific Patient Population of Treatment-Resistant Hypertension (TRH)
Treatment-Resistant Hypertension (TRH) Current Treatment and Medical Practices
Treatment-Resistant Hypertension (TRH) Unmet Needs
Treatment-Resistant Hypertension (TRH) Emerging Therapies
Treatment-Resistant Hypertension (TRH) Market Outlook
Country-Wise Treatment-Resistant Hypertension (TRH) Market Analysis (2022–2036)
Treatment-Resistant Hypertension (TRH) Market Access and Reimbursement of Therapies
Treatment-Resistant Hypertension (TRH) Market Drivers
Treatment-Resistant Hypertension (TRH) Market Barriers
Treatment-Resistant Hypertension (TRH) Appendix
Treatment-Resistant Hypertension (TRH) Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
